Amol Akhade: Belzutifan vs Everolimus for advanced RCC second line post IO plus TKI
Amol Akhade shared on LinkedIn:
“Belzutifan vs Everolimus for advanced RCC second line post IO plus TKI.
Inspite of exactly same median pfs ( 5.6 months in both arms ) and curves crossing each other) at second interim analysis at 18 months, PFS curves are well separated ( unequal censoring ??) and p value is 0.02 ( check RMST as curves cross each other).
This happens typically in IO drugs. Why targeted drugs show these kind of curves.
OS is numerically better but no statistical difference. P value is missing from OS KM curves – 0.20. Forest plot for OS are intresting to see ( With all possible issues with sub group analysis forest plots – no p value of interaction given )
Overall , Belzutifan gives tough fight to Everolimus and somehow manages to beat it on PFS (or should I Say the other way round- Everolimus fought well ) in 746 patients LARGE (over powered ?). Congratulations to all Authors.”
Source: Amol Akhade/LinkedIn
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023